Innoviva Q2 FY26 swings to net loss of $83.4 million; revenue rises 19% to $119.6 million
INVA•Business updates and partnerships
Innoviva launched wholly owned Nortiva Bio to advance the LYNX long-acting oral drug delivery platform; signed a distribution and licensing deal with Dr. Reddy’s for XACDURO in select emerging markets.
Product sales and royalty revenue
Net product sales climbed 46% to $51.8 million, including U.S. sales of $36.6 million, up 26% year-over-year; royalty revenue totaled $59.8 million.
Q2 revenue rises while net loss widens
Innoviva posted Q2 total revenue of $119.6 million, up 19% year-over-year; operating income rose to $50.9 million.
Net loss widened to $83.4 million, or $1.14 a share, driven primarily by a $161 million unfavorable change in investment fair values.
